Literature DB >> 30312732

Progression from low- to high-grade in a glioblastoma model reveals the pivotal role of immunoediting.

Irene Appolloni1, Francesco Alessandrini1, Davide Ceresa1, Daniela Marubbi2, Eleonora Gambini1, Daniele Reverberi3, Fabrizio Loiacono3, Paolo Malatesta4.   

Abstract

The mutual reshape of tumor and immune system cells during tumor progression is a widely accepted notion in different cancers including gliomas. The importance of this phenomenon in shaping glioma progression and the mechanisms governing it, however, are not fully elucidated. Taking advantage of a well-characterized in vivo glioma model we performed an analysis of glioma cells transcriptomes at different stages of progression and unveiled the reorganization of glioma-immune system interactions. Specifically, we show that the inability of low-grade glioma cells to orthotopically graft in syngeneic immunocompetent mice, positively correlates with the abundance of infiltrating lymphocytes in donor tumors and with a highly immunostimulatory transcriptional profile. Notably, during tumor progression glioma cells downregulate these genes and the immune infiltrate shifts towards a pro-tumorigenic phenotype. Challenging low-grade gliomas by grafting into immunodeficient hosts revealed the crucial role of the adaptive immune system in constraining glioma progression. Finally, we observed that although progression still takes place in immunodeficient mice, it is slower, likely due to a milder selection thus reinforcing the view of a pivotal role for the immune system in regulating glioma progression.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioblastoma; Immunoediting; PDGF-B; Retroviral induced glioma model; Tumor progression

Mesh:

Year:  2018        PMID: 30312732     DOI: 10.1016/j.canlet.2018.10.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.

Authors:  Francesco Alessandrini; Laura Menotti; Elisa Avitabile; Irene Appolloni; Davide Ceresa; Daniela Marubbi; Gabriella Campadelli-Fiume; Paolo Malatesta
Journal:  Oncogene       Date:  2019-02-12       Impact factor: 9.867

2.  CD8+ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas.

Authors:  Joshua R Kane; Junfei Zhao; Takashi Tsujiuchi; Brice Laffleur; Víctor A Arrieta; Aayushi Mahajan; Ganesh Rao; Angeliki Mela; Crismita Dmello; Li Chen; Daniel Y Zhang; Edgar González-Buendia; Catalina Lee-Chang; Ting Xiao; Gerson Rothschild; Uttiya Basu; Craig Horbinski; Maciej S Lesniak; Amy B Heimberger; Raul Rabadan; Peter Canoll; Adam M Sonabend
Journal:  Clin Cancer Res       Date:  2020-05-19       Impact factor: 12.531

3.  Cancer Immunoediting in Gliomas: Recent Advances and Implications for Immunotherapy.

Authors:  Parth V Shah; Víctor A Arrieta; Catalina Lee-Chang; Adam M Sonabend
Journal:  J Cell Immunol       Date:  2020

4.  Identification of Immunological Characteristics and Immune Subtypes Based on Single-Sample Gene Set Enrichment Analysis Algorithm in Lower-Grade Glioma.

Authors:  Yunyang Zhu; Songwei Feng; Zhaoming Song; Zhong Wang; Gang Chen
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

5.  Cdh4 Down-Regulation Impairs in Vivo Infiltration and Malignancy in Patients Derived Glioblastoma Cells.

Authors:  Davide Ceresa; Francesco Alessandrini; Lorenzo Bosio; Daniela Marubbi; Daniele Reverberi; Paolo Malatesta; Irene Appolloni
Journal:  Int J Mol Sci       Date:  2019-08-18       Impact factor: 5.923

6.  Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy.

Authors:  Adam M Sonabend; Roger Stupp; Catalina Lee-Chang; Hideho Okada
Journal:  Oncotarget       Date:  2021-01-05

7.  S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma.

Authors:  Yu Zhang; Xin Yang; Xiao-Lin Zhu; Hao Bai; Zhuang-Zhuang Wang; Jun-Jie Zhang; Chun-Yan Hao; Hu-Bin Duan
Journal:  Aging (Albany NY)       Date:  2021-06-08       Impact factor: 5.682

8.  Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma.

Authors:  Irene Appolloni; Francesco Alessandrini; Laura Menotti; Elisa Avitabile; Daniela Marubbi; Noemi Piga; Davide Ceresa; Francesca Piaggio; Gabriella Campadelli-Fiume; Paolo Malatesta
Journal:  Viruses       Date:  2021-08-24       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.